Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Arthritis, Psoriatic | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Ankylosing spondylitis (AS) | List with clinical criteria and/or conditions | Complete | ||
| Holkira Pak | Ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Holkira Pak | ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Hepsera | Adefovir dipivoxil | Hepatitis B | List with clinical criteria and/or conditions | Complete | ||
| Hepsera | Adefovir dipivoxil | Hepatitis B | Do not list | Complete | ||
| Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | ||
| Hemgenix | etranacogene dezaparvovec | Hemophilia B | Active |
Last Updated : May 3, 2024